StageAcquired | Acquired
About Design Clinicals
Design Clinicals is a healthcare information technology company dedicated to providing leading-edge tools to improve the delivery of patient care. The company offers intuitive software solutions that enhance communications and help improve workflow, patient safety and regulatory compliance goals. Products are highly adaptive, able to integrate with any hospital information system, with superior clinician adoption rates.
Missing: Design Clinicals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Design Clinicals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Design Clinicals News
Aug 20, 2013
First Databank (FDB) Acquires Medication Reconciliation Solution Leader Design Clinicals Acquisition enables FDB to enhance its ability to support hospitals in reconciling medications across the continuum of care and help them meet the requirements of Stages 1 and 2 of ARRA Meaningful Use August 20, 2013 06:03 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--First Databank (FDB), the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, today announced that an affiliate of FDB has acquired Design Clinicals, Inc., a healthcare information technology company dedicated to providing clinician-friendly solutions for improving medication reconciliation and the delivery of patient care. Design Clinicals, based in Seattle, Washington, began operations in 2005, is led by founder and CEO Dewey Howell, MD, PhD, a practicing family physician turned healthcare information technology software developer. Hospitals and clinicians are struggling to find efficient ways to manage the medication reconciliation process at each transition in care – admission, at transfer points and discharge. In fact, due to these challenges, medication reconciliation has been one of the most frequently deferred Meaningful Use Stage 1 menu objectives in attestations by eligible hospitals. With escalating Meaningful Use requirements, where medication reconciliation is now required for Stage 2, hospitals are turning to more effective methods to increase operational efficiency and information accuracy. “The Design Clinicals acquisition supports FDB’s mission of delivering solutions that help improve medication-related decisions,” said Bob Katter, executive vice president, FDB. “The optimal electronic medication reconciliation solution needs to incorporate intuitive drug knowledge and seamlessly integrate with the leading information system vendors. This is where the combined abilities of FDB and Design Clinicals are well positioned. We are extremely excited to combine our areas of expertise and partner with our customers to help make medication reconciliation work better for their clinicians and patients.” Design Clinicals’ flagship product, MedsTracker®, is a medication reconciliation software solution that integrates with an institution’s current CPOE, pharmacy and EMAR systems. It is actively deployed in 40 hospital sites across the United States and has helped customers satisfy the medication reconciliation patient safety goals of The Joint Commission. Additionally, MedsTracker currently holds modular certification for Stage 1 Meaningful Use for both ambulatory and inpatient practice for medication reconciliation and decision support and is in the process of securing modular certification for Stage 2. MedsTracker has demonstrated immediate and measurable improvements in the medication reconciliation process. Notable advances reported by customers include increased accuracy of home medication lists; efficiency of discharge medication orders and electronic prescribing; reductions in missed medications, duplicate therapies, and incorrect dosing; and workflow efficiencies with measurable time savings for clinicians. “When we first founded Design Clinicals, we partnered with FDB and built our entire platform around their drug knowledge and decision support tools,” said Dewey Howell, MD, PhD, Design Clinicals’ CEO. “I have always been impressed with FDB’s commitment to patient safety, clinician efficiency and overall quality. By joining forces, I am confident that together we will enable successful implementation of clinically-useful medication reconciliation and decision support.” “I am very impressed with the success that Dewey Howell has been able to achieve so quickly with Design Clinicals and MedsTracker,” said Chuck Tuchinda, MD, MBA, executive vice president, FDB. “He has helped solve a vexing industry problem. We will now work together to develop an embedded solution so that our health information system partners can more easily integrate this medication reconciliation functionality within their systems.” Effective immediately, Design Clinicals’ solutions are now available through FDB. Terms of the acquisition were not disclosed. About Design Clinicals Inc. Design Clinicals is a healthcare information technology company dedicated to providing leading-edge tools to improve the delivery of patient care. Founded in 2005 by practicing physicians and hospital IT professionals, Design Clinicals offers innovative, intuitive software solutions that enhance communications and help improve workflow, patient safety and regulatory compliance goals. Products are highly adaptive, able to integrate with any hospital information system, with superior clinician adoption rates. For more information, visit www.DesignClinicals.com About First Databank (FDB) First Databank (FDB) provides drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver a wide range of valuable, useful, and differentiated solutions. As the company that virtually launched the medication decision support category, we offer more than three decades of experience in transforming drug knowledge into actionable, targeted, and effective solutions that improve patient safety and healthcare outcomes. For a complete look at our solutions and services please visit www.fdbhealth.com or follow us on Twitter and LinkedIn . © 2013 First Databank, Inc. A subsidiary of Hearst Corporation. All trademarks mentioned herein are the properties of their respective owners. Contacts
Design Clinicals Frequently Asked Questions (FAQ)
Where is Design Clinicals's headquarters?
Design Clinicals's headquarters is located at 5200 Southcenter Blvd, Seattle.
What is Design Clinicals's latest funding round?
Design Clinicals's latest funding round is Acquired.
Who are the investors of Design Clinicals?
Investors of Design Clinicals include First Databank.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.